Literature DB >> 29709530

Beliefs influencing community pharmacists' interventions with chronic kidney disease patients: A theory-based qualitative study.

Patricia Quintana-Bárcena1, Lyne Lalonde2, Sophie Lauzier3.   

Abstract

BACKGROUND: Drug-related problems (DRPs) are highly prevalent in chronic kidney disease (CKD) patients. Community pharmacists are ideally positioned to manage these DRPs. However, little is known about the factors influencing their interventions with CKD patients.
OBJECTIVES: Using the theory of planned behavior (TPB), this qualitative study sought to: (1) explore the behavioral beliefs (perceived advantages and disadvantages), normative beliefs (perceived expectations of significant others) and control beliefs (perceived barriers and facilitators) influencing community pharmacists' interventions related to identifying and managing DRPs in CKD; and (2) compare these beliefs among three DRPs prevalent in CKD patients.
METHODS: Community pharmacists in Quebec, Canada participated in face-to-face individual semi-structured interviews. The topic guide was based on the TPB. Three vignettes were presented to stimulate community pharmacists' thoughts about their interventions regarding: (1) the use of an inappropriate over-the-counter laxative; (2) prescriptions of anti-inflammatory medications; and (3) non-adherence to antihypertensive medication. Integral transcripts of audio recordings were analyzed using thematic analysis. The findings on each of the three DRPs were systematically compared.
RESULTS: Fifteen community pharmacists participated in the study. All expressed a positive attitude toward DRP management, mentioning advantages such as gaining the patient's loyalty as a client and avoiding CKD complications. Participants mentioned that patients and physicians generally approve their interventions, but the dynamics of these relationships may vary depending on the DRP. Common barriers in the management of the three DRPs were the pharmacists' limited time and heavy workloads. The pharmacists felt that the main disadvantage is that these interventions interrupt the workflow in the pharmacy.
CONCLUSION: Community pharmacists hold positive views of their interventions in CKD. However, enhancing community pharmacists' involvement in CKD care may require measures to facilitate pharmacists' proactivity, inter-professional collaboration and a work organization adapted to clinical activities.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease; Community pharmacy; Drug-related problems; Pharmaceutical interventions; Qualitative study; Theory of planned behavior

Mesh:

Year:  2018        PMID: 29709530     DOI: 10.1016/j.sapharm.2018.04.004

Source DB:  PubMed          Journal:  Res Social Adm Pharm        ISSN: 1551-7411


  4 in total

1.  Importance of pharmacist-patient relationship in people living with HIV and concomitant opioid use disorder.

Authors:  Alina Cernasev; Michael P Veve; Kenneth C Hohmeier; Nathan A Summers; Santosh Kumar
Journal:  Explor Res Clin Soc Pharm       Date:  2021-07-31

2.  Clinical Pharmacy Activities Documented (ClinPhADoc): Development, Reliability and Acceptability of a Documentation Tool for Community Pharmacists.

Authors:  Nour Hamada; Patricia Quintana Bárcena; Karen Alexandra Maes; Olivier Bugnon; Jérôme Berger
Journal:  Pharmacy (Basel)       Date:  2019-12-02

3.  Patients' and healthcare professionals' beliefs, perceptions and needs towards chronic kidney disease self-management in China: a qualitative study.

Authors:  Hongxia Shen; Rianne M J J van der Kleij; Paul J M van der Boog; Wenjiao Wang; Xiaoyue Song; Zhengyan Li; Xiaoping Lou; Niels Chavannes
Journal:  BMJ Open       Date:  2021-03-04       Impact factor: 2.692

4.  Implementation of a Real-Time Medication Intake Monitoring Technology Intervention in Community Pharmacy Settings: A Mixed-Method Pilot Study.

Authors:  Sadaf Faisal; Jessica Ivo; Ryan Tennant; Kelsey-Ann Prior; Kelly Grindrod; Colleen McMillan; Tejal Patel
Journal:  Pharmacy (Basel)       Date:  2021-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.